TCTR20240615001已完成不适用
The Relationship of Phosphatidylinositol 3 Kinase Expression to Grading and Metastasis in Luminal Subtype Breast Cancer Patients
Self funding0 个研究点目标入组 74 人开始时间: 2024年6月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 17 Years 至 65 Years（—）
- 性别
- Female
入选标准
- •The Inclusion Criteria included female breast cancer patients aged 17 to 65 years with the luminal subtype, a normal BMI, metastatic or non-metastatic disease, and willingness to participate in the study.
排除标准
- •Exclusion criteria included luminal subtype breast cancer patients with positive HER2/Neu immunohistochemistry examinations, the presence of other malignancies (colorectal cancer, liver cancer, lung cancer, brain cancer), or tissue samples not suitable for immunohistochemistry examination (discohesion, denaturation).
研究者
相似试验
暂停
不适用
Effect of phosphodiesterase-3 inhibition with pimobendan on exercise capacity in heart failure with preserved left ventricular ejection fractioHFpEF (heart failure with preserved ejection fraction) with RV-PA uncouplingJPRN-jRCTs051210187Sakata Yasushi88
尚未招募
1 期
Based on PI3K/AKT/HIF-1 signaling pathway, to explore the clinical efficacy and mechanism of Zuoguiyin intervention in oxidative stress in the treatment of premature ovarian insufficiencyPremature ovarian insufficiencyITMCTR2023000069Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
Unknown
不适用
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneHormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast CancerNCT02109913Amsterdam UMC, location VUmc175
Unknown
1 期
TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN LossSafety IssuesEfficacy, SelfNCT04690725Peking University People's Hospital29
已完成
不适用
PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with hormone receptor-positive advanced metastatic breast cancer, who have progressed on anastrozole or letrozoleadvanced metastatic breast cancer10006291breast cancerNL-OMON46855Vrije Universiteit Medisch Centrum175